Open Access. Powered by Scholars. Published by Universities.®
- Keyword
- Publication
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Does Inorganic Mercury Play A Role In Alzheimer's Disease? A Systematic Review And An Integrated Molecular Mechanism, Joachim Mutter, Annika Curth, Johannes Naumann, Richard Deth, Harald Walach
Does Inorganic Mercury Play A Role In Alzheimer's Disease? A Systematic Review And An Integrated Molecular Mechanism, Joachim Mutter, Annika Curth, Johannes Naumann, Richard Deth, Harald Walach
Richard Deth
Mercury is one of the most toxic substances known to humans. It has been introduced into the human environment and has also been widely used in medicine. Since circumstantial evidence exists that the pathology of Alzheimer’s disease (AD) might be in part caused or exacerbated by inorganic mercury, we conducted a systematic review using a comprehensive search strategy. Studies were screened according to a predefined protocol. Two reviewers extracted relevant data independent of each other. One thousand and forty one references were scrutinized, and 106 studies fulfilled the inclusion criteria. Most studies were case control or comparative cohort studies. Thirty-two …
Cost-Effectiveness Of Lowering Blood Pressure With A Fixed Combination Of Perindopril And Indapamide In Type 2 Diabetes Mellitus: An Advance Trial-Based Analysis, Paul Glasziou, Philip Clarke, Jan Alexander, Mohana Rajmokan, Elaine Beller, Mark Woodward, John Chalmers, Neil Poulter, Anushka Patel
Cost-Effectiveness Of Lowering Blood Pressure With A Fixed Combination Of Perindopril And Indapamide In Type 2 Diabetes Mellitus: An Advance Trial-Based Analysis, Paul Glasziou, Philip Clarke, Jan Alexander, Mohana Rajmokan, Elaine Beller, Mark Woodward, John Chalmers, Neil Poulter, Anushka Patel
Elaine Beller
Objective: To determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus.
Design, setting and participants: Prospective cost-effectiveness analysis within the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, an international, multicentre, randomised controlled trial of 11 140 participants with type 2 diabetes randomly allocated to receive perindopril plus indapamide (4mg-1.25mg/day) or placebo.
Main outcome measures: Health-related quality-of-life measured by the EuroQol-5D, resource utilisation, and cost-effectiveness (cost per death averted at 4.3 years' average follow-up, and …